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ABSTRACT 
BACKGROUND: In treating orthopedic infections, the 
long-term impact of vancomycin therapy on colonization by 
methicillin-resistant Staphylococcus aureus (MRSA) and 
the emergence of vancomycin-intermediate S. aureus is 
unknown. 
DESIGN: Prospective surveillance of the effect of long-
term vancomycin therapy on colonization by MRSA and the 
emergence of vancomycin-intermediate S. aureus. 
METHODS: Thirty-four patients with MRSA osteo-
myelitis that was microbiologically documented were longitudi-
nally observed for the emergence of vancomycin-intermediate S. 
aureus at 3 body sites (wound, anterior nares, and groin) during 
the initial period of vancomycin therapy and at the 2-month fol-
low-up. Twenty patients received the standard dose (20 
mg/kg/d) for 34 ± 6 days and 14 patients received a high dose 
(40 mg/kg/d) of vancomycin for 37 ± 9 days. 
RESULTS: During vancomycin treatment, global MRSA 
carriage (all body sites) fell from 100% to 25% in the group of 
patients receiving the standard dose of vancomycin, and from 
100% to 40% in the group receiving the high dose. During the 2-
month follow-up period after vancomycin therapy, global MRSA 
carriage increased from 25% to 55% in the group receiving the 
standard dose and decreased from 43% to 36% in the group receiv-
ing the high dose. 
CONCLUSION: Therapy with a high dose of vancomycin 
contributes to the sustained eradication of MRSA carriage with-
out promoting the emergence of glycopeptide resistance (Infect 
Control Hosp Epidemiol 2003;24:650-654). 
The prevention and treatment of methicillin-resis-
tant Staphylococcus aureus (MRSA) infections represent 
an increasingly difficult challenge due to the emergence 
of multidrug-resistant strains. An additional concern is 
the recent discovery of MRSA isolates that exhibit 
decreased susceptibility to glycopeptides, including van-
comycin,1"4 which raises the possibility of organisms 
exhibiting global resistance to all currently available 
antibiotics.5 These isolates may demonstrate either inter-
mediate susceptibility or resistance to vancomycin.6 
Detection of vancomycin resistance is particularly diffi-
cult in most clinical isolates determined as either hetero-
geneous vancomycin-intermediate S. aureus (VISA)2 or 
heterogeneous vancomycin-resistant S. aureus (VRSA).1"3 
Several clinical and epidemiologic reports indicate 
that nasal and extranasal carriage of MRSA may predispose 
targeted groups of patients to invasive infections and con-
tribute to the nosocomial dissemination of these dangerous 
pathogens.7 Because patients with osteomyelitis caused by 
MRSA usually require several weeks of parenteral adminis-
tration of vancomycin, they should theoretically be at risk for 
the emergence of glycopeptide-resistant subpopulations.8"10 
Paradoxically, there has been no study evaluating the impact 
of long-term vancomycin therapy on the risk of emergence 
of VISA or VRSA in either infected or colonized body sites of 
patients treated for MRSA osteomyelitis. Although the use of 
mupirocin for topical MRSA decontamination has shown 
some efficacy for prophylaxis of orthopedic infections,11 its 
impact on multiple carriage sites of patients treated for 
MRSA osteomyelitis has not been reported. 
The aim of this study was to evaluate the influence 
of prolonged vancomycin therapy for MRSA osteomyelitis 
on the persistence of MRSA carriage and the potential 
emergence of VISA or VRSA in sequentially cultured body 
sites during the first 4-week period of antimicrobial thera-
py and at the 2-month follow-up. 
M E T H O D S 
Population and Study Design 
Between October 1998 and September 2001, we 
enrolled 39 adult patients consecutively admitted to a specif-
ically designed orthopedic septic unit at the University 
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Hospital of Geneva. The criteria for eligibility included 
microbiologically proven osteomyelitis with a pure culture 
of MRSA from a bone biopsy and intravenous vancomycin 
therapy for a minimum of 4 weeks. Five patients were 
excluded due to incomplete vancomycin therapy, allergy to 
vancomycin, or incomplete microbiological data. 
The first subgroup of enrolled patients (from 
October 1998 to November 2000) were treated intra-
venously with a standard dose (20 mg/kg/d) of van-
comycin (Eli Lilly, Geneva, Switzerland), whereas the sec-
ond subgroup of enrolled patients (from December 2000 
to December 2001) received a high dose (40 mg/kg/d) of 
intravenous vancomycin. The treatment was then adjust-
ed to obtain a trough vancomycin concentration in the 
serum of 20 to 25 mg/L in the group receiving the high 
dose, or 10 to 15 mg/L in the group receiving the stan-
dard dose, and to have a peak less than 50 mg/L. 
Thereafter, samples were taken only weekly or if an 
increase in serum creatinine was noted. 
During the first week of vancomycin therapy, all 
patients received applications of 4% chlorhexidine soap 
(Hibiscrub, Zeneca Pharma, Cergy, France) for daily 
body cleansing and 2% intranasal calcium mupirocin 
(Bactroban Nasal, SmithKline Beecham, Thorishaus, 
Switzerland) for 5 days. In addition, each patient remain-
ing a MRSA carrier at any body site (wound, nose, or 
groin) during hospitalization was placed in contact isola-
tion according to the established guidelines of our institu-
tion12 until eradication was assessed by 2 consecutive 
negative surveillance cultures. 
Microbiologic Evaluation 
All patients were screened for MRSA immediately 
before starting vancomycin therapy. Swabs (Copanswabs, 
Copan Italia S.p.A., Brescia, Italy) were taken from the 
anterior nares, the groin, and any wound, if present. 
Qualitative cultures were performed after enrichment 
in Staphylococcus Broth NaCl (Difco Laboratories, Sparks, 
MD) for 24 hours and subculturing on sheep blood agar. 
Identification of S. aureus was based on the morphology of 
colonies, the presence of clumping factor or protein A 
(Pastorex, Bio-Rad, Steinach, Switzerland), and the produc-
tion of heat-stable nuclease (Bacto DNase test agar [Difco 
Laboratories] and toluidine blue O [Merck, Darmstadt, 
Germany]). Each MRSA isolate was routinely monitored for 
its overall antimicrobial susceptibility by disk diffusion 
(Sirscan, v2a, Montpellier, France) according to National 
Committee for Clinical Laboratory Standards guidelines,13 
and finally stored at -70° C. Follow-up screening cultures for 
MRSA were performed weekly in all 3 sites during the ini-
tial 4-week period of therapy and at least once during the 2-
month follow-up period. The eradication of MRSA was 
defined by at least 3 negative culture sets from body sites. 
Susceptibility Testing 
From each patient in whom MRSA was not eradi-
cated during vancomycin therapy, 1 pre-therapy, 1 on-ther-
apy (at 3 to 4 weeks), and 1 post-therapy isolate were 
screened for the presence of subpopulations growing on 
brain-heart infusion agar supplemented with 2 ug/mL of 
vancomycin. One hundred microliters of a bacterial sus-
pension adjusted to the McFarland Standard Indicator 2.0 
(ATB 1550, API bioMerieux, Marcy l'Etiole, France) 
(approximately 5 X 108 colony-forming units [CFU]/mL) 
was spread onto vancomycin brain-heart infusion agar. S. 
aureus strains American Type Culture Collection 29213 
and mu50 were used as the negative and positive quality 
control strains, respectively.2 Any colony recovered from 
the agar at 48 hours was further tested for vancomycin 
minimum inhibitory concentration (MIC) by the Etest. 
All strains of MRSA were also tested for the potential 
presence of VISA or heterogeneous VISA by the Etest (AB 
BIODISK, Solna, Sweden) using the McFarland 2.0 inocu-
lum.14 VISA isolates were defined as having a vancomycin 
MIC ranging between 4 and 16 ug/mL, according to the 
breakpoints of the French Microbiology Society.15 The 
VISA control was the mu50 strain. 
Strain Typing 
Epidemiologic typing of sequential MRSA isolates 
was performed by pulsed-field gel electrophoresis 
(PFGE) (Pulsaphor system, Pharmacia LKB 
Biotechnology, Uppsala, Sweden) of chromosomal DNA 
digested with restriction endonuclease Smal (Bio-Rad, 
Hercules, CA), according to established protocols.16 The 
clonality of MRSA-persistent isolates was evaluated on 
specimens collected at baseline, on-therapy (at 3 to 4 
weeks), and during follow-up. Clonal diversity was defined 
by Tenover et al.17 
Therapeutic Regimens and Assessment of 
Serum Levels of Vancomycin 
Peak or trough serum levels of vancomycin were 
measured with the TDX Analyzer (Abbott Laboratories, 
Vienna, Austria) at 30 minutes following the 1-hour infu-
sion or immediately before the next infusion, respectively. 
Data Analysis 
In this study, the demographic and clinical informa-
tion that was recorded included age and gender, underlying 
diseases, type and stage of osteomyelitis, type of van-
comycin regimen, serum levels of vancomycin, and other 
associated antibiotics. Continuous variables were present-
ed as the mean and standard deviation or median if their 
distribution was skewed. Yates-corrected chi-square or 
Fisher's exact tests were used to assess changes between 
the observed proportions of unrelated samples. A P value 
of less than .05 was considered statistically significant. 
Statistical analysis was performed using Analyse-it software 
(version 1.62; Analyse-it Software LTD, Leeds, England) for 
Excel 2002 (Microsoft Corp., Redmond, WA). 
RESULTS 
Patients and Vancomycin Treatment 
Thirty-four patients (20 men and 14 women) with a 
mean age of 66.2 ± 16.1 years (range, 37 to 77 years) treat-
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TABLE 
CHARACTERISTICS 
VANCOMYCIN 
Characteristic 
OF ORTHOPEDIC PATIENTS TREATED WITH 
Vancomycin Regimen 
Standard Dose High Dose 
(20 mg/kg/d) (40 mg/kg/d) 
SD - standard deviation. 
*Cierny-Mader classification: stage 1 = intramedullary osteomyelitis (infected intramedullary 
rod); stage 2 - superficial osteomyelitis; stage 3 = localized osteomyelitis (full-thickness, cortical 
sequestration); and stage 4 = diffuse osteomyelitis (fracture with non-union, infected prosthesis). 
included ankle, wrist, or phalangeal. 
tRifampin and ciprofloxacin were used in combination with vancomycin in 8 patients and 1 
patient, respectively. 
ed for MRSA osteomyelitis with vancomycin for a minimum 
of 4 weeks fulfilled all criteria to be enrolled in this study. 
There was no significant difference in the major baseline 
demographic and clinical characteristics of patients treated 
with the standard (n = 20) or high (n = 14) dose of van-
comycin, including age, gender, duration of therapy, 
implant-associated infection, and major underlying diseases 
(Table). The localization and severity of osteomyelitis was 
similar in patients treated with the standard dose or the 
high dose of vancomycin. Nine patients (4 in the group 
receiving the standard dose and 5 in the group receiving 
the high dose) were diagnosed as having an acute 
osteomyelitis, whereas 25 patients suffered from a chronic 
infection (duration, longer than 4 weeks). Twenty-six 
patients (14 receiving the standard dose and 12 receiving 
the high dose) initially presented with an open wound 
(chronic fistula or breakdown of a wound following 
surgery). 
Twenty patients received a standard dose (20 
mg/kg/d) and 14 patients a high dose (40 mg/kg/d) of 
vancomycin for 34 ± 6 and 37 ± 9 days, respectively. Serum 
levels of vancomycin were used for adjusting the stan-
dard- or high-dose regimens of intravenous vancomycin to 
target trough serum levels of 10 to 15 mg/L and 20 to 25 
mg/L, respectively. The mean (± standard deviation) 
serum trough levels in patients receiving the standard 
and high doses of vancomycin were 11.4 ± 7.1 mg/L and 
21.8 ± 5.9 mg/L, respectively. Eight patients received 
another systemic antibiotic combined with vancomycin; 3 
receiving the standard dose and 4 receiving the high 
dose, respectively, received rifampin and 1 patient receiv-
ing a high dose received ciprofloxacin. 
Rate of MRSA Colonization During and After 
Glycopeptide Therapy 
At baseline, 100% of the patients had MRSA 
osteomyelitis that was microbiologically documented (by 
bone biopsy). In the group receiving the standard dose of 
vancomycin, 9 (45%) of the 20 patients were colonized in 
the anterior nares and 6 (30%) in the groin. In comparison, 
at the onset of therapy with a high dose of vancomycin, 10 
(71%) of the 14 patients were colonized in the nares and 9 
(64%) in the groin. 
During vancomycin treatment, MRSA nasal carriage 
fell from 45% to 5% in the group receiving the standard dose 
of vancomycin, and from 71% to 14% in the group receiving 
the high dose (no significant difference). MRSA groin car-
riage fell from 30% to 10% in the standard-dose group, and 
from 64% to 21% in the high-dose group (no significant dif-
ference). The global MRSA carriage (all body sites) fell 
from 100% to 25% in the standard-dose group, and from 
100% to 40% in the high-dose group (no significant differ-
ence). During the 2-month period following therapy with 
the standard dose of vancomycin, 6 of 15 previously decol-
onized patients were recolonized with MRSA, shifting the 
overall colonization rate for this period from 25% to 55%. 
During the 2-month follow-up period after therapy 
with a high dose of vancomycin, overall MRSA carriage at 
any site did not increase, but marginally decreased from 
43% to 36% (Figure). Patients treated with a high dose of 
vancomycin had a significantly higher probability (P = 
.048) of remaining free of MRSA during the follow-up peri-
od than did patients treated with the standard dose. 
An analysis of risk factors showed that among the 
residual MRSA carriers treated with vancomycin, most 
still had open wounds. Except for the vancomycin dose, 
no factors (eg, underlying diseases, implant-associated 
infection, or other associated antibiotics) should be asso-
ciated with a risk of residual MRSA carriage. 
Genetic Relatedness of MRSA Specimens 
In the 16 patients who were persistently or recur-
rently colonized with MRSA during follow-up screening, 
PFGE was used to evaluate the genetic relatedness of pre-
treatment and follow-up strains. In all 16 patients, 11 who 
received the standard dose and 5 who received the high 
dose, the relatedness of persistently or recurrently colo-
No. of patients 20 14 
Mean age, y (± SD) 67 (± 18) 66 (± 12) 
Male (%) 10 (50) 8 (57) 
No. with underlying diseases (%) 
Chronic renal failure 4 (20) 4 (29) 
Diabetic disease 6 (30) 7 (50) 
No. with osteomyelitis (%) 
Cierny-Mader, stage 3 or 4* 7 (35) 6 (43) 
Localization of osteomyelitis 
Foot-phalangeal 
Femur-hip 
Tibia-knee 
Othert 
Implant-associated infection (%) 
No. who underwent surgical 
procedures (%) 
Vancomycin regimen 
Mean trough serum level, 
mg/L (± SD) 
Mean duration of treatment, 34 (± 6) 37 (± 9) 
d (± SD) 
No. of patients with other 5 (25) 4 (29) 
antibiotics (%)' 
9(45) 
4(20) 
4(20) 
3(15) 
4(20) 
17 (84) 
11.4 (± 7.1) 
7(50) 
3(21) 
3(21) 
1(8) 
4(29) 
11 (79) 
21.8 (± 5.9) 
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nizing strains of MRSA was confirmed and no patient 
became recolonized with a new strain. 
Analysis of Vancomycin Susceptibility 
The potential emergence of VISA or heterogeneous 
VISA was determined by comparing follow-up isolates with 
related pretreatment isolates in the 16 persistent or recur-
rent MRSA carriers. Among the 51 MRSA isolates tested, 
none yielded any significant subpopulation (more than 10 
CFU) that demonstrated decreased vancomycin suscepti-
bility on agar supplemented with 2 ug/mL of vancomycin. 
The screening of subpopulations on brain-heart infusion 
agar supplemented with 2 ug/mL of vancomycin was used 
to avoid extensive population analysis studies on all MRSA 
isolates. For the few MRSA isolates that yielded colonies 
growing on agar containing 2 ug/mL of vancomycin, fur-
ther testing demonstrated that none of these colonies 
could grow on agar supplemented with higher concentra-
tions (ie, 4 or 6 ug/mL) of vancomycin, nor did any exhib-
it a significant increase in vancomycin MIC by the Etest. 
Evaluation of the 51 MRSA isolates by the Etest 
yielded identical MICs (median MIC, 1.5 ug/mL; range, 1 
to 2 ug/mL) for fdllow-up MRSA isolates from 11 carriers 
treated with the standard dose of vancomycin and 5 carri-
ers treated with the high dose. In no patient was there any 
trend for the emergence of VISA or heterogeneous VISA 
during the long-term intravenous therapy with either the 
standard or high dose. 
DISCUSSION 
This study evaluated the impact of long-term par-
enteral vancomycin therapy on MRSA carriage or eradica-
tion at 3 body sites and the potential emergence of van-
comycin resistance in hospitalized orthopedic patients 
treated for osteomyelitis. The 2 groups of patients treated 
with vancomycin received a similar 1-week protocol of top-
ical decontamination with mupirocin and chlorhexidine, 
but differed from each other by receiving either a standard 
or high dose of parenteral vancomycin. Whereas eradica-
tion of MRSA carriage occurred in 75% and 57% of the 
patients treated for 4 weeks with the standard or high dose 
of vancomycin, respectively, recolonization observed dur-
ing the 2-month post-therapy period occurred mainly in the 
group receiving the standard dose. Decolonization of the 
nares essentially occurred during the first week of therapy. 
Overall, these data indicate the efficacy of mupirocin 
applied intranasally. But this efficacy is temporary because 
previously decolonized patients in the group receiving the 
standard dose of vancomycin were recolonized with MRSA 
during the fourth week and 2-month period of follow-up. 
However, no recolonization occurred among patients in the 
group receiving the high dose. All persisting or relapsing 
MRSA isolates were identical to pre-therapy isolates and 
remained fully susceptible to vancomycin during the obser-
vation period, regardless of the serum levels of vancomycin 
obtained during therapy or duration of antibiotic exposure. 
Whereas many studies have been performed to 
evaluate the efficacy of topical or systemic antimicrobial 
Wk 1 Wk 2 Wk 3 Wk 4 Follow-up 
FIGURE. Global (nares, groin, and wound) rate of methicillin-resistant 
Staphylococcus aureus (MRSA) colonization during and after vancomycin 
therapy: standard dose (20 mg/kg/d) versus high dose (40 mg/kg/d). *During 
the 2-month follow-up period after therapy with a high dose of vancomycin, 
overall MRSA carriage at any site did not increase, but marginally decreased 
from 43% to 36%. Patients treated with a high dose of vancomycin had a 
higher probability (P = .048) of remaining free of MRSA during the follow-up 
period than did patients treated with a standard dose. 
regimens for nasal and extranasal MRSA carriage, con-
flicting data on their efficacy have been reported.18 True 
comparisons among the different studies are difficult 
because more than 40 different decolonization regimens 
have been tested in past decades18; intranasal application 
of mupirocin, by far the most effective topical agent, has 
limited effectiveness in eradicating extranasal MRSA col-
onization1819; and randomized or nonrandomized prospec-
tive studies were performed mostly with noninfected 
patients in attempts to decrease the incidence of S. aureus 
infections in special risk groups2021 or before orthopedic11 
or cardiothoracic surgery.22,23 When topical decontamina-
tion, frequently associated with systemic antimicrobial 
therapy, was used for controlling endemic or epidemic 
conditions of MRSA transmission, even more heteroge-
neous results have been reported.24"30 The discrepancy in 
the success rates reported in these studies may result not 
only from the different regimens of antimicrobials used 
for MRSA decontamination such as co-trimoxazole, 
rifampin, ciprofloxacin, minocycline, rifampin, and fusidic 
acid, but also from the highly different clinical and epi-
demiologic situations of targeted groups. However, these 
studies did determine that combined regimens of antimi-
crobial agents were superior to single agents such as 
rifampin, quinolone, or fusidic acid, with each of these 
potentially leading to the rapid emergence of antibiotic 
resistance.3134 
This study was facilitated by the well-established 
MRSA surveillance system in the orthopedic septic unit of 
our hospital, which involves routine preoperative and post-
operative microbiological screening of each patient. To 
optimize the penetration of vancomycin into bones infected 
with MRSA and its efficacy, therapy with a higher dose of 
vancomycin was initiated in our institution in 2001.10'35'36 
The possible relationship between the duration or amount 
of vancomycin tiierapy and the development of resistance 
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is still under debate.37'40 Despite that more than 50% of 
patients presenting with VISA received long-term van-
comycin treatment (29 days to 18 weeks), these isolated 
cases did not establish a statistically valid relationship 
between overall vancomycin use and the emergence of gly-
copeptide resistance.38 Because most clinical isolates pre-
sent as heterogeneous VISA, and thus might represent an 
intermediate step toward the development of more highly 
resistant organisms,41 we found it appropriate to perform 
our screening assays at a low concentration (2 ug/mL) of 
vancomycin. This procedure, added to the Etest with a high 
inoculum, was rapid and efficient for the detection of trends 
of emerging vancomycin resistance. 
Therapy with a high dose of vancomycin may con-
tribute to the elimination of MRSA carriage without pro-
moting the emergence of glycopeptide resistance. 
Further studies are warranted to evaluate a larger group 
of patients during longer follow-up periods. 
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